“…PGI 2 plays a key role in limiting Th2-mediated airway inflammation (Jaffar, Wan, & Roberts, 2002) and pretreatment with PGI 2 results in considerably attenuated pulmonary inflammation and airway hyperreactivity in mice in response to ovalbumin inhalation (Jaffar, Ferrini, Buford, Fitzgerald, & Roberts, 2007). A novel sustained-release prostacyclin analog, ONO-1301MS, attenuates monocrotaline-induced pulmonary hypertension in rats (Obata et al, 2008) and its action is associated with a marked reduction of TXA 2 (Murakami et al, 2006). The repeated administration of ONO-1301 can attenuate the development of bleomycin-induced pulmonary fibrosis and improve survival in bleomycin mice by inhibiting TXA 2 synthesis (Murakami et al, 2006).…”